Anna V. Wojcicki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Anna V. Wojcicki has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Kathleen M. Sakamoto
Division of Hematology/Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA
2 shared publications - Norman J. Lacayo
Division of Hematology, Oncology, and Stem Cell Transplantation & Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, CA
2 shared publications - Adam Frymoyer
Division of Neonatology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA
1 shared publication Anna K. Kopec
Department of Pathobiology and Diagnostic Investigation, Michigan State University, East Lansing, MI, USA; Institute for Integrative Toxicology, Michigan State University, East Lansing, MI, USA
1 shared publicationBradley P. Sullivan
Department of Pathobiology and Diagnostic Investigation, Michigan State University, East Lansing, MI, USA; Current affiliation: Pfizer Inc., Lake Forest, IL, USA
1 shared publicationBrendan F. Johnson
Michigan State University-Department of Energy Plant Research Laboratory, USA
1 shared publication
Latest Publications
- 1 August 2020
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 130 (4) , 230-238
Metabolomics in acute myeloid leukemia
- 1 August 2020
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 130 (4) , 230-238
Metabolomics in acute myeloid leukemia
- Open Access
Repurposing Drugs for Acute Myeloid Leukemia: A Worthy Cause or a Futile Pursuit?
Acute myeloid leukemia (AML) is a clinically and genetically heterogenous malignancy of myeloid progenitor cells that affects patients of all ages. Despite decades of research and improvement in overall outcomes, standard therapy remains ineffective for certain subtypes of AML. Current treatment is intensive and leads to a number of secondary effects with varying results by patient population. Due to the high cost of discovery and an unmet need for new targeted therapies that are well tolerated, alternative drug development strategies have become increasingly attractive. Repurposing existing drugs is one approach to identify new therapies with fewer financial and regulatory hurdles. In this review, we provide an overview of previously U.S. Food and Drug Administration (FDA) approved non-chemotherapy drugs under investigation for the treatment of AML.
Open AccessRepurposing Drugs for Acute Myeloid Leukemia: A Worthy Cause or a Futile Pursuit?
Acute myeloid leukemia (AML) is a clinically and genetically heterogenous malignancy of myeloid progenitor cells that affects patients of all ages. Despite decades of research and improvement in overall outcomes, standard therapy remains ineffective for certain subtypes of AML. Current treatment is intensive and leads to a number of secondary effects with varying results by patient population. Due to the high cost of discovery and an unmet need for new targeted therapies that are well tolerated, alternative drug development strategies have become increasingly attractive. Repurposing existing drugs is one approach to identify new therapies with fewer financial and regulatory hurdles. In this review, we provide an overview of previously U.S. Food and Drug Administration (FDA) approved non-chemotherapy drugs under investigation for the treatment of AML.
- 1 April 2017
- Published by Elsevier in Journal of Hepatology
- Vol. 66 (4) , 787-797
Fibrin(ogen) drives repair after acetaminophen-induced liver injury via leukocyte αMβ2 integrin-dependent upregulation of Mmp12
- 1 April 2017
- Published by Elsevier in Journal of Hepatology
- Vol. 66 (4) , 787-797
Fibrin(ogen) drives repair after acetaminophen-induced liver injury via leukocyte αMβ2 integrin-dependent upregulation of Mmp12